Posts

Posted on

Qualigen Therapeutics Announces Inclusion in Russell Microcap® Index

CARLSBAD, Calif., June 08, 2021 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today that according to a preliminary list of additions posted June 4 it will be added to the Russell Microcap Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective on June 28, 2021.

Membership in the Russell Microcap® Index means automatic inclusion in the appropriate growth and value indexes. FTSE Russell determines membership for its indexes primarily by objective, market-capitalization rankings as well as style attributes.

“We are excited that Qualigen Therapeutics will be included in the widely referenced Russell Microcap Index, with some of the most innovative public companies in the U.S. For Qualigen, it reflects the company’s progress toward advancing our promising oncology and viral disease pipeline programs,” stated Michael Poirier, Chairman and Chief Executive Officer at Qualigen Therapeutics.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell’s U.S. indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell Microcap Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.

About Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core FDA-approved FastPack® System, which has been used successfully in diagnostics for 20 years. Our cancer therapeutics pipeline includes QN-247 (formerly referred to as ALAN or AS1411-GNP), RAS-F and STARS™. QN-247 is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects; the nanoparticle coating technology is similar to the core nanoparticle coating technology used in our blood-testing diagnostic products. The foundational aptamer of QN-247, QN-165 (formerly referred to as AS1411), is also a drug candidate for treating COVID-19 and other viral-based infectious diseases; we currently plan that our first clinical trial would be a trial of QN-165 against COVID-19. RAS-F is a family of RAS oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins; preventing this binding could stop tumor growth, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device candidate for removal from circulating blood of precisely targeted tumor-produced and viral compounds.

Because Qualigen’s therapeutic candidates are still in the development stage, Qualigen’s only products that are currently commercially available are FastPack System diagnostic instruments and test kits, used in physician offices, clinics and small hospitals around the world.

The FastPack System menu includes rapid point-of-care diagnostic tests for cancer, men’s health, hormone function, and vitamin D status. Qualigen’s facility in Carlsbad, California is FDA and ISO Certified and its FastPack product line is sold worldwide by its commercial partner Sekisui Diagnostics, LLC.

For more information on Qualigen Therapeutics, Inc., please visit https://www.qualigeninc.com.

About FTSE Russell

FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally.

FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $17.9 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives.

A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.

FTSE Russell is wholly owned by London Stock Exchange Group.

For more information, visit www.ftserussell.com.

Forward-Looking Statements

This news release contains forward-looking statements by the Company that involve risks and uncertainties and reflect the Company’s judgment as of the date of this release. These statements include those related to the Company’s prospects and strategy for the development of therapeutic drug candidates. Actual events or results may differ from the Company’s expectations. For example, there can be no assurance that clinical trials will be approved to begin by or will proceed as contemplated by any projected timeline; that the Company will successfully develop any drugs or therapeutic devices; that preclinical or clinical development of the Company’s drugs or therapeutic devices will be successful; that future clinical trial data will be favorable or that such trials will confirm any improvements over other products or lack negative impacts; that any drugs or therapeutic devices will receive required regulatory approvals or that they will be commercially successful; that patents will issue on the Company’s owned and in-licensed patent applications; that such patents, if any, and the Company’s current owned and in-licensed patents would prevent competition; that the Company will be able to procure or earn sufficient working capital to complete the development, testing and launch of the Company’s prospective therapeutic products; or that the Company will be able to maintain or expand market demand and/or market share for the Company’s diagnostic products. The Company’s stock price could be harmed if any of the events or trends contemplated by the forward-looking statements fails to occur or is delayed or if any actual future event otherwise differs from expectations. Additional information concerning these and other risk factors affecting the Company’s business (including events beyond the Company’s control, such as epidemics and resulting changes) can be found in the Company’s prior filings with the Securities and Exchange Commission, available at www.sec.gov. The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investor Relations:

For further information: David Kugelman
Atlanta Capital Partners, LLC
(404) 856-9157 or (866) 692-6847 Toll Free – U.S. & Canada
[email protected]

Tony Schor
Investor Awareness, Inc.
(847) 971-0922
[email protected]



Posted on

Video-Technology Provider Glimpse Joins PAR Technology’s Brink POS® Integration Partner Ecosystem

Video-Technology Provider Glimpse Joins PAR Technology’s Brink POS® Integration Partner Ecosystem

NEW HARTFORD, N.Y.–(BUSINESS WIRE)–ParTech, Inc. (PAR), a global restaurant technology company and Unified Commerce Cloud Platform for Enterprise Restaurants, today announced it has added another name to its industry-leading Brink POS integration partner ecosystem. Glimpse is an all-in-one restaurant and bar software service created to help operators keep track of inventory, monitor employee performance, and discover lost revenue using the power of artificial intelligence (AI).

With the impacts of COVID making waves throughout the industry, operators are under more pressure to manage costs consistently and effectively. Glimpse uses video analysis to identify areas of opportunity in quick service restaurants to increase speed of service and improve food production times.

“Computer vision technology and automation are undoubtedly a vital part of the restaurant industry of the future,” said Paul Radu, CEO of Glimpse. “Glimpse is excited to collaborate with PAR to introduce foodservice operators across all categories and operating models to this technology service, ultimately helping eliminate losses and cost-efficiently glean critical insights into day-to-day operations.”

Slow service and long customer wait times can cripple a restaurant’s bottom line. Glimpse provides operators with valuable insights into their restaurant’s activities, including employee and store sales performance and guest through-put. Streamlined reports are available via text apps or email. Customers have used the Glimpse service to see increases in speed of service, waste reduction, and, for one customer, more than $45,000 in annual savings.

“We’re pleased to have Glimpse join the Brink POS partner ecosystem,” said Chad Horn, Director of Strategic Partnerships for PAR. “AI technology is giving restaurant operators more visibility into how their business is performing in real-time, and then using that information to make better decisions, save money, and collect more revenue. Glimpse is helping to pull really valuable insights out of video, without making it difficult to access and understand what is happening.”

ABOUT GLIMPSE

Glimpse is a technology service provider in the foodservice industry supporting owners and operators reduce waste and improve profitability; the automated loss-prevention and data analysis video-technology measures and reports unaccounted sales (and theft), evaluates employee order accuracy, service speed, production time, customer traffic and wait times, all in one place. The seamless POS integration and data collection allow for rapid installation, onboarding, and reporting. Reports are presented in a clear dashboard with various personalized notifications available for any mobile device.

ABOUT PAR TECHNOLOGY

For more than 40 years, PAR’s (NYSE Symbol: PAR) cutting-edge products and services have helped bold and passionate restaurant brands build lasting guest relationships. We are the partner enterprise restaurants rely on when they need to serve amazing moments from open to close, during the most hectic rush hours, and when the world forces them to adapt and overcome. More than 100,000 restaurants in more than 110 countries use PAR’s restaurant hardware, software, drive-thru, and back-office solutions. With the recent acquisition of leading loyalty solutions provider Punchh Inc., PAR has become a Unified Commerce Cloud Platform for Enterprise Restaurants. To learn more, visit www.partech.com or connect with us on LinkedIn, Twitter, Facebook, and Instagram.

Christopher R. Byrnes (315) 743-8376

[email protected], www.partech.com

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Food/Beverage Retail Other Technology Technology Software

MEDIA:

Logo
Logo
Posted on

ClearPoint Neuro, Inc. Congratulates BlueRock Therapeutics on First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson’s Disease

First Ever Stem Cell Clinical Trial Patient Treated Using Entire ClearPoint Platform

SOLANA BEACH, Calif., June 08, 2021 (GLOBE NEWSWIRE) — ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, on the dose administration for the first patient in a Phase 1, open-label study of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson’s disease (PD). The clinical trial, designed to evaluate the safety, tolerability, and preliminary efficacy of DA01 in patients with PD, is expected to enroll ten patients at sites in the United States and Canada.

The surgery, which represents the first ever delivery of stem cell-derived dopaminergic neurons using the ClearPoint platform, was performed by Dr. Viviane Tabar, Chair of the Department of Neurosurgery and Theresa Feng Chair in Neurosurgical Oncology at Memorial Sloan Kettering Cancer Center. Dr. Tabar utilized the ClearPoint Neuro Navigation System with two SmartFrames, and six SmartFlow cannulae to surgically transplant dopamine-producing cells into the putamen under live-MRI guidance. The Company’s clinical specialist team provided support during the dose administration and assisted the study team to execute the MRI workflow which ClearPoint helped design for the clinical trial protocol.

Parkinson’s disease is a progressive neurodegenerative disorder caused by nerve cell damage in the brain, leading to decreased dopamine levels. The worsening of motor and non-motor symptoms is caused by the loss of dopamine-producing neurons. At diagnosis, it is estimated that patients have already lost 60-80% of their dopaminergic neurons. Parkinson’s disease often starts with a tremor in one hand. Other symptoms are rigidity, cramping and slowness of movement (bradykinesia). Parkinson’s disease is the second most common neurodegenerative disorder, impacting more than 7.5 million people globally, including 1.3 million people in North America.1 It is estimated that approximately 60,000 Americans are diagnosed with PD each year.2

“ClearPoint is proud to contribute to BlueRock’s efforts to explore authentic cell treatments and routes of administration under live-image guidance for patients with advanced Parkinson’s disease, and beyond,” stated Jeremy Stigall, Vice President, Biologics and Drug Delivery. “We look forward to supporting additional trial patients and activated sites.”

More information about this trial is available at clinicaltrials.gov (NCT#04802733).


About ClearPoint Neuro

ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company’s current product portfolio include deep brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 60 active sites in the United States, Canada, and Europe. ClearPoint Neuro is partnered with over 30 biologics/pharmaceutical companies and academic centers, providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, more than 4,500 cases have been performed and supported by the Company’s field-based clinical specialist team, which offers support and services for our partners. For more information, please visit www.clearpointneuro.com.


Forward-Looking Statements

Statements herein concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company’s future events, developments and future performance, as well as management’s expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company’s actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of COVID-19 and the measures adopted to contain its spread; future revenues from sales of the Company’s ClearPoint Neuro Navigation System products; and the Company’s ability to market, commercialize and achieve broader market acceptance for the Company’s ClearPoint Neuro Navigation System products. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, and the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2021, both of which have been filed with the Securities and Exchange Commission.

______________________________

1 https://bluerocktx.com/pipeline/
2 https://www.parkinson.org/Understanding-Parkinsons/Statistics#:~:text=Approximately%2060%2C000%20Americans%20are%20diagnosed,worldwide%20are%20living%20with%20PD.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d375ef5e-925f-4976-8bb2-63f3e90871a3



Contact:

Jacqueline Keller, Vice President, Marketing
1 (888) 287-9109
[email protected]

Caroline Corner, Investor Relations
[email protected]

Posted on

Osama Musa, Ashland chief technology officer and expert team of scientists publish six-volume handbook of pyrrolidone and caprolactam based materials

WILMINGTON, Del., June 08, 2021 (GLOBE NEWSWIRE) — Ashland Global Holdings (NYS:ASH) today announced that Osama Musa, Ph.D., senior vice president and chief technology officer, Ashland and an expert team of scientists have published a six volume book, “The Handbook of Pyrrolidone and Caprolactam Based Materials: Synthesis, Characterization and Industrial Applications.”

Pyrrolidone and caprolactam based materials have very interesting, diverse properties and functionalities that shape everyday life. This handbook details the broad human benefits of the materials within thirty-two chapters, many of which are from the chemist’s viewpoint.

“I am proud of Osama and our talented team of scientists who worked diligently, dedicating personal time to publish a detailed and modern portrait of pyrrolidone and caprolactam based materials for the world today and their future possibilities,” said Guillermo Novo, chairman and chief executive officer, Ashland. “This comprehensive handbook unites the functionality of pyrrolidone and caprolactam based materials with relevant science critical for our customers, consumers and a circular economy.”

“Ashland is truly a specialty materials company,” said Osama Musa, senior vice president and chief technology officer, Ashland. “This handbook emphasizes our capabilities to provide designer materials and innovations, and to customize solutions for complex challenges. It enables readers to appreciate these diverse capabilities and broad ranging applications more fully. The handbook also reinforces Ashland’s ability to adapt to ever-changing technology needs and consumer megatrends as diverse as sustainability to healthy aging and more.”   

Volume one presents the chemistry of small lactam-based molecules, uncovering their unique properties. The discussion builds the necessary foundations required for a fundamental understanding of how the molecules enable a myriad of commercially important applications.

The second volume explores the physical chemistry and molecular interactions of pyrrolidone and caprolactam based materials. It reviews homopolymerization, copolymerization, controlled radical polymerization and acrylate based pyrrolidone polymerizations. Pyrrolidone functionalization of natural and synthetic polymers is also discussed and presents a rich and diverse polymer landscape relevant to today‘s technical challenges and opportunities. This volume is dedicated to the memory of Michael A. Tallon, an Ashland scientist who spent several decades working on the study of these materials.

Volume three reviews the physical chemistry and molecular interactions of pyrrolidone and caprolactam based materials ranging from cocrystals and coordination complexes to solution properties, characterization techniques and computational chemistry. State-of-the-art techniques provide insight into the origins of the structure and properties of the materials.

The fourth volume includes detailed discussions of nuclear magnetic resonance and Fourier transform-infrared spectroscopy, thermal and mechanical properties, and imaging techniques as applied to various phenomena involving pyrrolidone and caprolactam materials.

Volumes five and six explore relevant commercial subjects including applications in consumer and industrial end markets such as pharmaceutical, hair care, skin care, oral care, home care, adhesives, digital printing, coatings and more.  Safety, toxicology, and antimicrobial topics are also reviewed along with the technical rationale for the nearly ubiquitous nature of these materials.  

Published by Wiley, the handbook is now available online by visiting
Handbook of Pyrrolidone and Caprolactam Based Materials: Synthesis, Characterization and Industrial Applications, 6 Volume Set | Wiley


https://www.wiley.com/en-us/Handbook+of+Pyrrolidone+and+Caprolactam+Based+Materials:+Synthesis,+Characterization+and+Industrial+Applications,+6+Volume+Set-p-9781119468738?prevItm=657263368&prevCol=6340491&ts=174535

A recent interview with Musa about sustainability as part of Ashland’s business strategy can be found here
https://www.wiley.com/network/professionals/sustainability/green-growth-opportunities-sustainability-in-the-chemical-industry-2

About Ashland 
Ashland Global Holdings Inc. (NYSE: ASH) is a premier specialty materials company with a conscious and proactive mindset for sustainability. The company serves customers in a wide range of consumer and industrial markets, including adhesives, architectural coatings, automotive, construction, energy, food and beverage, nutraceuticals, personal care and pharmaceutical. Approximately 4,200 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com and ashland.com/sustainability  to learn more. 

FOR FURTHER INFORMATION:

Media Relations: 
Carolmarie Brown 
+1(302) 995-3158 
[email protected]

Attachment



Posted on

Climate Change Crisis Real Impact I Acquisition Corporation and EVgo to Host Fireside Chat Today with IPO Edge to Discuss Business Combination

Climate Change Crisis Real Impact I Acquisition Corporation and EVgo to Host Fireside Chat Today with IPO Edge to Discuss Business Combination

NEW YORK–(BUSINESS WIRE)–
Climate Change Crisis Real Impact I Acquisition Corporation (NYSE: CLII) (“CRIS”), a publicly-traded special purpose acquisition company, and EVgo Services LLC (“EVgo”), the nation’s largest public fast charging network for electric vehicles (“EVs”) and first powered by 100% renewable electricity, announced that the companies will host a fireside chat with IPO Edge today, Tuesday, June 8 at 2pm EDT, to discuss their pending business combination.

The live event will feature David Crane, CEO of CRIS, and Cathy Zoi, CEO of EVgo. IPO Edge Editor-in-Chief John Jannarone will moderate the video session which will include a Q&A session with the audience.

To register, CLICK HERE.

To view IPO Edge’s announcement about today’s fireside chat, CLICK HERE.

Mr. Crane and Ms. Zoi will discuss:

  • An overview of the business combination and investment highlights
  • The supportive fundamentals driving EV growth and adoption and demand for EV fast charging
  • The evolution of the SPAC market and involvement of more individual investors
  • Why it is important for all record date shareholders to vote, regardless of how many shares they own
  • How investors vote shares through their brokers

“We remain committed to engaging with all our investors, and believe it is especially important as we approach the final steps of our business combination with EVgo,” said Mr. Crane. “In partnership with IPO Edge, we look forward to highlighting EVgo’s leadership position and its significant opportunity for long-term growth in the climate critical electrification of transport sector, discussing the voting process and its importance, and addressing investor questions. We hope to hear from you at today’s virtual event.”

Shareholder Vote Information

The Special Meeting to approve the pending business combination is scheduled to be held on June 29, 2021 at 10:00 a.m. Eastern Time. The Special Meeting will be conducted completely virtually, and can be accessed via live webcast at https://www.cstproxy.com/climatechangecrisisrealimpacti/2021. If the proposals at the Special Meeting are approved, the parties anticipate that the business combination will close shortly thereafter, subject to the satisfaction or waiver, as applicable, of all other closing conditions.

Every stockholder’s vote is important, regardless of the number of shares held. Accordingly, CRIS requests that each stockholder of record as of the close of business on May 19, 2021 (the “Record Date”), vote as soon as possible and by no later than June 28, 2021 to ensure that the stockholder’s shares will be represented at the Special Meeting. CRIS’s board of directors recommends you vote “FOR” the Business Combination with EVgo and “FOR” all of the related proposals described in the definitive proxy statement on Schedule 14A (the “Proxy Statement”) filed by CRIS with the Securities and Exchange Commission (“SEC”) on May 27, 2021.

Stockholders who owned common stock of CRIS as of the Record Date continue to have the right to vote their shares for the Special Meeting, regardless of whether such stockholders subsequently sold their shares and do not own such shares as of the date they cast their vote.

Additional information is available at https://www.climaterealimpactsolutions.com/cris1-vote. Investors are encouraged to contact Morrow Sodali LLC, CRIS’s proxy solicitor, with questions or for assistance via e-mail at [email protected] or toll-free call at (800) 662-5200

Important Information and Where to Find It

In connection with the proposed business combination between EVgo and CRIS and related transactions (the “Proposed Transactions”), CRIS has filed the Proxy Statement with the SEC, which was distributed to holders of CRIS’s common stock in connection with CRIS’s solicitation of proxies for the vote by CRIS’s stockholders with respect to the Proposed Transactions and other matters as described in the Proxy Statement. Investors and security holders and other interested parties are urged to read the Proxy Statement, and any amendments thereto and any other documents filed with the SEC carefully and in their entirety because they contain important information about CRIS, EVgo and the Proposed Transactions. Investors and security holders may obtain free copies of the Proxy Statement and other documents filed with the SEC by CRIS through the website maintained by the SEC at http://www.sec.gov, or by directing a request to: Climate Change Crisis Real Impact I Acquisition Corporation, 300 Carnegie Center, Suite 150, Princeton, New Jersey 08540. The information contained on, or that may be accessed through, the websites referenced in this press release is not incorporated by reference into, and is not a part of, this press release.

Participants in the Solicitation

CRIS and EVgo and their respective directors and certain of their respective executive officers and other members of management and employees may be considered participants in the solicitation of proxies with respect to the Proposed Transactions. Information about the directors and executive officers of CRIS and EVgo is set forth in the Proxy Statement. Stockholders, potential investors and other interested persons should read the Proxy Statement carefully before making any voting or investment decisions. These documents can be obtained free of charge from the sources indicated above.

Forward Looking Statements

Certain statements in this press release that are not historical facts may constitute forward-looking statements are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. All statements, other than statements of present or historical fact included in this press release, regarding CRIS’s proposed business combination with EVgo, CRIS’s ability to consummate the transaction, the benefits of the transaction and the combined company’s future financial performance, as well as the combined company’s strategy, future operations, estimated financial position, estimated revenues and losses, projected costs, prospects, plans and objectives of management are forward-looking statements. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the respective management of CRIS and EVgo and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of CRIS or EVgo. Potential risks and uncertainties that could cause the actual results to differ materially from those expressed or implied by forward-looking statements include, but are not limited to, changes in domestic and foreign business, market, financial, political and legal conditions; the inability of the parties to successfully or timely consummate the business combination, including the risk that any regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the business combination or that the approval of the stockholders of CRIS or EVgo is not obtained; failure to realize the anticipated benefits of business combination; risk relating to the uncertainty of the projected financial information with respect to EVgo; the amount of redemption requests made by CRIS’s stockholders; the overall level of consumer demand for EVgo’s products; general economic conditions and other factors affecting consumer confidence, preferences, and behavior; disruption and volatility in the global currency, capital, and credit markets; the financial strength of EVgo’s customers; EVgo’s ability to implement its business strategy; changes in governmental regulation, EVgo’s exposure to litigation claims and other loss contingencies; disruptions and other impacts to EVgo’s business, as a result of the COVID-19 pandemic and government actions and restrictive measures implemented in response; stability of EVgo’s suppliers, as well as consumer demand for its products, in light of disease epidemics and health-related concerns such as the COVID-19 pandemic; the impact that global climate change trends may have on EVgo and its suppliers and customers; EVgo’s ability to protect patents, trademarks and other intellectual property rights; any breaches of, or interruptions in, CRIS’s information systems; fluctuations in the price, availability and quality of electricity and other raw materials and contracted products as well as foreign currency fluctuations; changes in tax laws and liabilities, tariffs, legal, regulatory, political and economic risks. More information on potential factors that could affect CRIS’s or EVgo’s financial results is included from time to time in CRIS’s public reports filed with the SEC, as well as the Proxy Statement that CRIS has filed with the SEC in connection with CRIS’s solicitation of proxies for the meeting of stockholders to be held to approve, among other things, the proposed business combination. If any of these risks materialize or CRIS’s or EVgo’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither CRIS nor EVgo presently know, or that CRIS and EVgo currently believe are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect CRIS’s and EVgo’s expectations, plans or forecasts of future events and views as of the date of this press release. CRIS and EVgo anticipate that subsequent events and developments will cause their assessments to change. However, while CRIS and EVgo may elect to update these forward-looking statements at some point in the future, CRIS and EVgo specifically disclaim any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing CRIS’s or EVgo’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

No Offer or Solicitation

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities.

About CRIS

CRIS is a special-purpose acquisition company (“SPAC”) formed to identify and acquire a scalable company making significant contributions to the fight against the climate crisis. CRIS is co-sponsored by private funds affiliated with Pacific Investment Management Company LLC (“PIMCO”), which has more than $640 billion in sustainability investments across its portfolios. CRIS is led by a seasoned operations and leadership team that has decades of experience at the intersection of climate change and capitalism, and includes veterans from NRG, Credit Suisse, General Electric and Green Mountain Power. For more information, please visit www.climaterealimpactsolutions.com/.

About EVgo

EVgo is the nation’s largest public fast charging network for electric vehicles, and the first to be powered by 100% renewable energy. With more than 800 fast charging locations, EVgo’s charging network serves over 65 metropolitan areas across 34 states, owns and operates the most public fast charging locations in the US. and serves more than 250,000 customers. Founded in 2010, EVgo leads the way on transportation electrification, partnering with automakers; fleet and rideshare operators; retail hosts such as hotels, shopping centers, gas stations and parking lot operators; and other stakeholders to deploy advanced charging technology to expand network availability and make it easier for drivers across the U.S. to enjoy the benefits of driving an EV. As a charging technology first mover, EVgo works closely with business and government leaders to accelerate the ubiquitous adoption of EVs by providing a reliable and convenient charging experience close to where drivers live, work and play, whether for a daily commute or a commercial fleet. EVgo’s parent company is LS Power, a New York-headquartered development, investment and operating company focused on leading edge solutions for the North American power and energy infrastructure sector. On January 22, 2021, EVgo announced that it entered into a definitive business combination agreement with CRIS (NYSE: CLII). For more information visit evgo.com and lspower.com.

CRIS

For Investors:

Dan Gross

[email protected]


For Media:

Isaac Steinmetz

Director of Media Relations

[email protected]

646-883-3655

EVgo

For Investors:

[email protected]

For Media:

[email protected]


LS Power

Steven Arabia

Director, Government Affairs & Media Relations

[email protected]

609-212-3857

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Other Transport Other Professional Services Transport Other Technology Finance Consulting Professional Services Technology Other Energy Utilities Other Communications Public Relations/Investor Relations Alternative Energy Energy Communications Other Travel Transportation Public Transport Travel

MEDIA:

Posted on

InflaRx Doses First Patient in Multicenter Phase II Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab

  • Proof-of-concept trial will evaluate vilobelimab alone and in combination with pembrolizumab

JENA, Germany, June 08, 2021 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced the enrollment of the first patient in an open-label, multicenter Phase II clinical study evaluating vilobelimab alone and in combination with pembrolizumab in patients with PD-1 or PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC).

The Phase II clinical trial is expected to enroll approximately 70 patients at sites in Europe, the U.S. and elsewhere. The study will investigate two independent arms: vilobelimab alone and vilobelimab in combination with pembrolizumab. The main objectives of the trial are to assess the safety and antitumor activity of vilobelimab monotherapy and to determine the maximum tolerated or recommended dose, safety and antitumor activity in the combination arm.

Dr. Korinna Pilz, Global Head of Clinical Research and Development at InflaRx, said: “We are pleased to initiate the first clinical trial to evaluate vilobelimab in cancer. Scientific data suggest C5a involvement in tumor formation and progression, as well as in immunosuppression. Additionally, there is pre-clinical evidence of synergies between PD-1 and C5a/C5aR inhibitors in inducing anti-tumor responses. Based on this, we believe that vilobelimab has the potential alone and in combination with the PD-1 checkpoint inhibitor pembrolizumab to treat the advanced stages of this potentially deadly skin cancer.”

The C5a/C5aR pathway has been implied as a potential driver for tumorigenesis, metastases and avoidance of immune cell destruction, particularly in the context of cSCC.

Several independent pre-clinical studies showed that the combination of a C5a or C5aR pathway inhibitor with inhibition of the PD-1/PD-L1 axis leads to an antitumoral effect, which was stronger than inhibition of one of the axes alone. This provides a pre-clinical rationale for the combined blockade of PD-1 and C5a to restore antitumor immune responses and to inhibit tumor cell growth.

About cutaneous squamous cell carcinoma (cSCC)

cSCC is the second most common form of skin cancer and, if caught early, it is generally curable. In the U.S. alone, according to the Skin Cancer Foundation, an estimated 1.8 million cases are diagnosed each year, which translates to about 205 cases diagnosed every hour. The incidence of cSCC has increased up to 200 percent in the past three decades. Over 15,000 people in the U.S. die each year from this disease. Approximately 5% of patients with cSCC develop locally advanced or metastatic disease. These forms of cSCC have a poor prognosis with low survival rates.

About vilobelimab (IFX-1):

Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood. Thus, vilobelimab leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism, which is not the case for molecules blocking the cleavage of C5. Vilobelimab has been demonstrated to control the inflammatory response driven tissue and organ damage by specifically blocking C5a as a key “amplifier” of this response in pre-clinical studies. Vilobelimab is believed to be the first monoclonal anti-C5a antibody introduced into clinical development. Approximately 300 people have been treated with vilobelimab in clinical trials, and the antibody has been shown to be well tolerated. Vilobelimab is currently being developed for various indications, including Hidradenitis Suppurativa, ANCA-associated vasculitis, Pyoderma Gangraenosum and COVID-19 pneumonia.

About InflaRx N.V.:

InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com.

Contacts:

InflaRx N.V.

Jordan Zwick – Chief Strategy Officer
Email: [email protected]
Tel: +1 917-338-6523

MC Services AG

Katja Arnold, Laurie Doyle, Andreas Jungfer
Email: [email protected]
Europe: +49 89-210 2280
US: +1-339-832-0752

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential” or “continue” and similar expressions. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials; the impact of the COVID-19 pandemic on the Company; the timing and our ability to commence and conduct clinical trials; potential results from current or potential future collaborations; our ability to make regulatory filings, obtain positive guidance from regulators, and obtain and maintain regulatory approvals for our product candidates; our intellectual property position; our ability to develop commercial functions; expectations regarding clinical trial data; our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies; the industry in which we operate; the trends that may affect the industry or us and the risks uncertainties and other factors described under the heading “Risk Factors” in InflaRx’s periodic filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.



Posted on

Lithia Motors & Driveway (LAD) Adds $185 Million of Revenue

PR Newswire

MEDFORD, Ore., June 8, 2021 /PRNewswire/ — Lithia Motors & Driveway (NYSE: LAD) announced today the acquisition of two locations in Van Nuys, California, serving the greater Los Angeles area. BMW of Sherman Oaks and Acura of Sherman Oaks are expected to generate combined annualized revenues of $185 million.

“We welcome the BMW of Sherman Oaks and Acura of Sherman Oaks teams to the LAD family,” said Bryan DeBoer, Lithia & Driveway’s President and CEO. “We are excited to add our first BMW store in Southern California and capture the significant potential that exists.”

LAD has acquired nearly $7.1 billion in annualized revenues since the launch of its five-year plan to reach $50 billion in revenues and $50 in earnings per share just under a year ago. This growth has been focused primarily in the Southeast and Central regions where their network density is lightest. LAD has a robust pipeline of over $15 billion in annualized revenues in discussion and priced to meet their disciplined hurdle rates. “We are well ahead of schedule on the network development portion of our five-year plan. Our network is essential to conveniently and affordably meet the needs of our customers throughout their entire vehicle ownership lifecycle.” This value-based transaction was financed using existing on-balance sheet capacity.

About Lithia Motors & Driveway:
Lithia Motors & Driveway is a growth company powered by people and innovation with a 5-year plan to profitably consolidate the largest retail sector in the country. They are a leading provider of personal transportation solutions in the United States and are among the fastest-growing companies in the Fortune 500 (#6 on 10-Year EPS Growth, #4 10-Year TSR in 2020). By providing a wide array of products throughout the entire lifecycle of the consumer’s vehicle ownership experience through various consumer channels, they build magnetic brand loyalty. Operational excellence is achieved by focusing the business on convenient and transparent consumer experiences supported by proprietary data science to increase market share, consumer loyalty and team performance. Lithia’s omni-channel strategy will continue to pragmatically disrupt the industry by leveraging experienced teams, vast owned inventories, technology, and physical network. By purchasing strong businesses, they further strengthen this network, leveraging their national digital home channel Driveway and building upon the massive regenerating capital engine. Together, these endeavors create a unique and compelling high-growth strategy that provides transportation solutions wherever, whenever, and however consumers desire.

Company Websites 
www.lithiamotors.com 
www.lithiainvestorrelations.com 
www.lithiacareers.com 
www.driveway.com

Lithia Motors on Facebook 
https://www.facebook.com/LithiaMotors

Lithia Motors on Twitter 
https://twitter.com/lithiamotors

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/lithia-motors–driveway-lad-adds-185-million-of-revenue-301307493.html

SOURCE Lithia Motors, Inc.

Posted on

QIWI Appoints Chief Executive Officer

NICOSIA, Cyprus, June 08, 2021 (GLOBE NEWSWIRE) — QIWI plc (NASDAQ: QIWI) (MOEX: QIWI) (“QIWI” or the “Company”), a leading provider of next generation payment and financial services in Russia and the CIS, today announced the appointment of Andrey Protopopov as Chief Executive Officer effective June 2, 2021. As Chief Executive Officer, Mr. Protopopov will take over the responsibilities of Boris Kim.

Mr. Protopopov has long played a vital role at QIWI, in particular, its product development function. Prior to his current position as the Chief Executive Officer of Payment Services Segment, Mr. Protopopov has served as Head of IT and Product from June 2015 to August 2019 and Head of Product Management from September 2013 to June 2015. Mr. Protopopov has over 12 years of commercial and product managing experience. Before joining QIWI, Mr. Protopopov worked at Procter & Gamble for 12 years, holding numerous positions in market strategy and planning as well as business development.

Mr. Protopopov graduated from Novosibirsk State University in 2004 with a Master degree in mathematics.

“Andrey has done a tremendous job during his eight years with the Company. I am inspired to see him at the helm of our Company and the directions he will take it in. As a founder and long-running ex-CEO of QIWI myself, I am confident that Andrey has the drive and the vision to position QIWI for continued success. His appointment comes after a thorough and careful succession planning process, spearheaded by the Board and Boris Kim himself,” commented Mr. Sergey Solonin, QIWI’s Chairman of the Board of Directors. “Moreover, I truly believe that Andrey possesses the right mix of operational CEO experience, leadership skills, and technology industry expertise required to elevate QIWI to the next level,” added Mr. Solonin.

“I am truly honored to lead QIWI as the Chief Executive Officer,” said Mr. Protopopov. “I look forward to continuing to work closely with our exceptional senior leadership team, along with Sergei, as our Chairman, and our entire Board of Directors. QIWI unites the team of most talented people at the payment market aiming to serve our clients with the most convenient digital solutions. Together, we will capture new growth opportunities, provide the best career experience to our employees and deliver additional value to our shareholders.”

About QIWI plc.

QIWI is a leading provider of next generation payment and financial services in Russia and the CIS. It has an integrated proprietary network that enables payment services across online, mobile and physical channels. It has deployed over 16.6 million virtual wallets, over 106,000 kiosks and terminals, and enabled merchants and customers to accept and transfer over RUB 128 billion cash and electronic payments monthly connecting over 29 million consumers using its network at least once a month. QIWI’s consumers can use cash, stored value and other electronic payment methods in order to pay for goods and services or transfer money across virtual or physical environments interchangeably.



Contact
Investor Relations
+357.25028091
[email protected]

Posted on

Domino’s® Urges Customers Not to Buy NFTs From the Noid™

Don’t be fooled, it’s just another scheme to foil pizza deliveries!

PR Newswire

ANN ARBOR, Mich., June 8, 2021 /PRNewswire/ — Domino’s Pizza Inc. (NYSE: DPZ), the largest pizza company in the world based on global retail sales, knows that the Noid is back and will stop at nothing to thwart great pizza deliveries. However, recent Noid innovations featured in the latest Domino’s television campaign, such as the infamous Pizza Crusher, Pizza Slayzer and giant Noid Balloon Blockade, haven’t stopped tech-savvy Domino’s from delivering delicious pizza to families nationwide. What’s a villain to do?

To Domino’s dismay, their nemesis has decided to sell one-of-a-kind nonfungible tokens (NFTs) linked to these tools, over the course of a fourteen-day auction, to fund future schemes. Domino’s was alerted to this nefarious plan and felt a strong statement was necessary: please don’t buy them!

NFTs are pieces of unique digital code stored on the blockchain, linked to underlying assets from images to GIFs to memes, and act as a permanent public ledger of transactions associated with those assets. They can be bought and sold or auctioned, including on special NFT marketplaces, and are often purchased with cryptocurrency.

Just days ago, the Noid created one-of-a-kind NFTs associated with its three latest inventions and placed them on https://rarible.com/thenoid for anyone to purchase. This NFT collection – more aptly called Noid’s Failed Tools – may look cleverly-designed, even down to the Noid’s unique signature emblazoned on each tool, but don’t be fooled by the devious creature’s ulterior motives.

“We saw the Noid fans on Twitter asking how they could get a Pizza Crusher. We get it, it looks pretty fun,” said Kate Trumbull, Domino’s vice president of advertising. “But who knows what pesky ideas the Noid will be able to fund with the proceeds from the NFT sale? It’s just best that everyone steers clear.”

While the Noid hasn’t revealed exactly what the proceeds will go towards, rumor has it that the anti-mascot is considering things like new and improved gadgets, ingenious disguises, or maybe an autobiography. There’s even been speculation that the Noid is plotting to hop on TikTok later this week to continue its foolish antics. The Noid is not lacking in ideas, just funds. Stop Domino’s archrival and Avoid the Noid™!

About Domino’s Pizza®
Founded in 1960, Domino’s Pizza is the largest pizza company in the world based on retail sales, with a significant business in both delivery and carryout pizza. It ranks among the world’s top public restaurant brands with a global enterprise of more than 17,800 stores in over 90 markets. Domino’s had global retail sales of over $16.1 billion in 2020, with nearly $8.3 billion in the U.S. and over $7.8 billion internationally. In the first quarter of 2021, Domino’s had global retail sales of over $4.0 billion, with nearly $2.0 billion in the U.S. and over $2.0 billion internationally. Its system is comprised of independent franchise owners who accounted for 98% of Domino’s stores as of the end of the first quarter of 2021. Emphasis on technology innovation helped Domino’s achieve more than half of all global retail sales in 2020 from digital channels. In the U.S., Domino’s generated more than 70% of sales in 2020 via digital channels and has developed several innovative ordering platforms, including those for Google Home, Facebook Messenger, Apple Watch, Amazon Echo, Twitter and more. In 2019, Domino’s announced a partnership with Nuro to further its exploration and testing of autonomous pizza delivery. In mid-2020, Domino’s launched a new way to order contactless carryout nationwide – via Domino’s Carside Delivery®, which customers can choose when placing a prepaid online order.

Order – dominos.com  
Company Info – biz.dominos.com
Media Assets – media.dominos.com

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/dominos-urges-customers-not-to-buy-nfts-from-the-noid-301307437.html

SOURCE Domino’s Pizza

Posted on

Welltower to Present at NAREIT 2021 Investor Conference

PR Newswire

TOLEDO, Ohio, June 8, 2021 /PRNewswire/ — Welltower® Inc. (NYSE: WELL) today announced that Shankh Mitra, CEO and CIO and Timothy G. McHugh, EVP and CFO, will present at NAREIT’s REITweek 2021 Investor Conference on Tuesday, June 8, 2021 from 11:00 a.m. – 11:30 a.m. Eastern Time.

To access the Company’s live presentation, please complete the complimentary registration for the conference at the following link: Nareit’s REITweek Registration. An on-demand recording will be available in the REITweek virtual environment for the remainder of the conference. For assistance with registering, please contact [email protected].

About Welltower

Welltower Inc. (NYSE: WELL), an S&P 500 company headquartered in Toledo, Ohio, is driving the transformation of health care infrastructure. The Company invests with leading seniors housing operators, post-acute providers and health systems to fund the real estate infrastructure needed to scale innovative care delivery models and improve people’s wellness and overall health care experience. Welltower®, a real estate investment trust (REIT), owns interests in properties concentrated in major, high-growth markets in the United States, Canada and the United Kingdom, consisting of seniors housing and post-acute communities and outpatient medical properties. More information is available at http://welltower.com/.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/welltower-to-present-at-nareit-2021-investor-conference-301307397.html

SOURCE Welltower Inc.